Merck KGaA (MRK) Earnings Call Transcript & Summary
May 12, 2022
Earnings Call Speaker Segments
Operator
operatorGood day, ladies and gentlemen, and welcome to the Merck Investor and Analyst Conference Call covering the first quarter of 2022. Please note that everyone joining us is in listen-only mode. At this point, I'll pass the floor to Constantin Fest, our Head of Investor Relations, who will guide you through today's conference. Over to you, sir.
Constantin Fest
executiveThanks so much, Kevin. A very warm welcome to this Merck Q1 2022 results call. I'm Constantin Fest, Head of Investor Relations at Merck. I'm delighted that joining me today are Belén Garijo, the group's CEO, and Marcus Kuhnert, CFO. Also with us for the Q&A portion of this call are Matthias Heinzel, CEO of Life Science, Peter Guenter, CEO of Healthcare, and Kai Beckmann, CEO for Electronics. We'd now like to take you through the key slides of this presentation, after which we'll move to our Q&A. With that, I'll hand things straight over to Belén Garijo, Group CEO, to kick off this presentation. Over to you.
Belén Garijo
executiveThanks a lot, Constantin, and hello everyone on my end as well for our Q1 earnings call. If you could turn to slide five in the deck, we'll begin with the highlights. All in all, we got off to a solid start, with the life science sector serving as the main engine. On an organic basis, group revenue rose by nearly 8%, while EBITDA pre climbed 1.6% versus demanding comparables in 2021. Combined with considerable currency tailwinds and a modest portfolio effect, reported sales reached EUR 5.2 billion and EBITDA pre came in at EUR 1.6 billion. Meanwhile, EPS pre stood at EUR 2.41, an 11% increase year-on-year. With supply chain and inflationary pressure building, the operating environment is getting tougher by the day, as all of you are well aware. Still, owing to the exceptional dedication of our teams around the world, we are handling these difficulties fairly well, and we keep delivering meaningful progress on our strategic agenda. On the back of the robust Q1 performance and a favorable outlook for the rest of 2022, we are now reaffirming our full year guidance. As is typical at this point in the year, we are becoming more precise, expecting net sales in a range of EUR 21.6 billion-EUR 22.8 billion and EBITDA pre of EUR 6.6 billion-EUR 7.1 billion, with EPS pre of 9.60 to 10.50.
Belén Garijo
executiveWe’ll get into the details of our assumptions a bit later in the presentation. If you turn to slide six, that gives you an overview of how we performed across our business sectors. As you can see, each of our three business sectors helped drive strong organic sales growth in Q1. Our key growth engines — what we call the Big Three, Process Solutions, and the new Healthcare launches — are very well on track. They account for almost 90% of the growth in the quarter. Life Science was again the main driver, with sales rising to 10% organically, followed by Healthcare at almost 7% and Electronics at 5%. Currency was a significant tailwind across all areas, adding 4.4 to group revenues and 6.4 to group EBITDA pre. The acquisition of Exelead, which closed at the end of February as you know, also contributed slightly to sales, while it is a slight drag on earnings because of phasing. Inside Life Science, growth came entirely from the strength of the core business, while COVID sales were slightly dilutive to growth and significantly down from Q4 levels. Even with lower COVID sales, Process Solutions continues to stand out, with 13% organic growth. Applied Solutions is on par this quarter, also delivering a remarkable 30%, while Research Solutions was up by 2% against the results comparables of Q1 2021.
Belén Garijo
executiveHealthcare saw solid organic growth, driven by 50%, 50% growth from recent launches — mainly MAVENCLAD and BAVENCIO — while the established portfolio held steady. Looking at it by franchise, oncology stood out as the quarter's highlight, posting organic growth of almost 30%. In electronics, our semi business turned in very strong organic growth of 16%, which more than offset the display decline, while surface edged slightly higher. On earnings, EBITDA pre reached EUR 1.63 billion, producing a strong margin of 31.3%, a bit lower year-on-year. Life science's margin, by contrast, rose, with EBITDA pre-growth of more than EUR 130 million in absolute terms. Turning to slide seven, you'll see sales broken down by region, and overall the performance was broad-based, with organic growth in every region. That's one more strong testament to how globally relevant our very well diversified portfolio is. Of our largest regions, Europe grew fastest in Q1, with sales up 11% organically, then Asia Pacific at 7%, and North America at 5%. Life science posted double-digit organic growth in all of these regions, while self-care and electronics rose in Europe and Asia Pacific. All told, our geographic footprint stays nicely balanced, with significant exposure to strategic growth markets in Asia Pacific at 36% of our sales, then Europe and North America, each at 28%.
Belén Garijo
executiveSo with that, I’ll pass the call to Marcus, who can give us a bit more detail on our Q1 results. Marcus, the floor is yours.
Marcus Kuhnert
executiveThanks a lot, Belén, and hello from me as well. I'll turn now to slide nine, which gives an overview of the key figures for Q1. All in all, 2022 got off to a solid start, with sales and earnings per share pre both growing at a double-digit rate. Allowing for substantial currency tailwinds and a modest portfolio effect stemming from the Exelead acquisition, net sales rose 12.2% to EUR 5.2 billion. EBITDA pre climbed 7.8% to EUR 1,629 million, while EPS pre was 10.6% higher at EUR 2.41. Operating cash flow reached EUR 840 million, a decline of 31% versus a year earlier, driven chiefly by phasing effects on payables and tax positions. Net financial debt went up by EUR 475 million relative to the end of December, largely because of the Exelead acquisition, and our ratio of net debt to EBITDA pre held steady at 1.4x. Now a few quick remarks on the reported results shown on slide 10. In absolute terms, EBITDA rose by EUR 130 million during the first quarter, essentially matching EBITDA pre. Financial results improved markedly, chiefly on the back of lower interest expenses resulting from reduced interest on tax liabilities and lower financial debt. The effective tax rate was 22.4%, placing it in the lower half of our guidance range.
Marcus Kuhnert
executiveBoth net income and reported EPS rose by over 17%. Now, let's proceed to the sector-by-sector review, beginning with Life Science, which is on slide 11. Life Science got off to a robust start this year, posting organic sales growth of 9.7%. Inside that, the core business performed strongly, with organic sales up 11%, whereas COVID sales were mildly dilutive to growth and well under Q4 levels. Looking at the portfolio, Process Solutions continues as a major growth engine, with sales rising 13% organically. There, the core business grew 15% organically, while the COVID effect swung negative to roughly -2%. Growth was led by bioprocessing, with actives and formulations following. We further expanded capacity in bottleneck areas, though output was temporarily hit by supply challenges early in the quarter. Order intake kept climbing despite difficult comparisons, and the order book stays solid. Research Solutions posted organic growth of 2.1%, which is impressive given very tough comparables. A healthy 5% organic increase in the core business was offset by softer COVID sales, which did rise sequentially, however, thanks to temporarily elevated testing activity during the Omicron wave. Applied Solutions enjoyed an excellent quarter, delivering organic growth of 13% in a robust market, with broad-based strength across every business line.
Marcus Kuhnert
executiveJust to remind everyone, COVID-related sales in Applied are minimal. Looking at geography, we posted double-digit organic growth across every major region. From a customer standpoint, industrial and testing as well as pharma and biotech each delivered double-digit organic growth, whereas academia came in slightly higher and diagnostics fell by double digits on weaker COVID demand. The lockdown in China had little effect on Q1. That said, we do anticipate a substantial impact in Q2. Turning to earnings, EBITDA pre surpassed the EUR 900 million threshold for the first time, up 12% organically at a record 37.9% margin. The +70 basis points of margin improvement mirror a positive product mix in the core business along with operating leverage and favorable pricing, partly offset by a smaller share of COVID business and continued strategic investments. With that said, please keep in mind that we still anticipate a modest margin decline for the full year. Turning to healthcare on slide 12. Healthcare likewise got the year off to a strong start, with sales rising 6.5% organically, fueled by, as Belén just noted, 50% growth from our recent launches and roughly flat sales in the established portfolio. Within franchises, oncology stood out as the top performer, with organic sales growth of 27%.
Marcus Kuhnert
executiveThe ongoing robust launch momentum for BAVENCIO drove this, particularly in Europe, where sales more than doubled compared with a year earlier, and Erbitux also delivered solid growth at +10%. Within our N&I franchise, we saw modest growth of roughly 1%: the continued erosion of Rebif at -15% was more than compensated for by the further ramp-up of MAVENCLAD, which grew +25% organically against a flat U.S. MS market. Our fertility franchise posted 4% organic growth, consistent with our midterm guidance, helped by GONAL-f gains across most markets. CM&E sales climbed 2.5% organically on the back of strong Euthyrox and Concor performance, whereas Glucophage declined because of still difficult comparables tied to the VBP program in China. Turning to our pipeline, I'll start with evobrutinib. Every pharma company conducting clinical studies in Ukraine and Russia has faced difficulties because of the war in Ukraine. In that respect, we are no different. As a result, we have put additional measures in place to safeguard the integrity of our studies, including seeking patients outside those countries. On the pipeline as well, we have moved enpatoran — our highly selective and potent dual TLR7/8 inhibitor — into phase II development. On earnings, EBITDA pre reached EUR 5.9 million, a decline of 7% organically, with a margin of 29.5%.
Marcus Kuhnert
executiveKeep in mind that the 300 basis points of margin contraction largely reflected difficult comparisons. More specifically, the first quarter of last year contained non-recurring income of approximately EUR 75 million, made up of roughly EUR 50 million for two BAVENCIO milestones, some EUR 20 million from GSK deferred income, and about EUR 5 million from active portfolio management. Non-recurring income in Q1 this year came to only around EUR 15 million, arising from active portfolio management and entirely consistent with our low double-digit million euro guidance. Once those differences in non-recurring income are adjusted for, the margin would have been roughly stable. With that said, we reaffirm our full year guidance for income from active portfolio management in the low to mid double-digit millions and anticipate a further low double-digit million EUR amount in the second quarter. Moving to Electronics on slide 13. Electronics got off to a solid start this year, with organic sales growth of 5.2%. Semiconductor Solutions continued as the key growth engine, with sales rising 16% organically, once again surpassing our midterm guidance. That strong performance was driven by mid-teens growth in semi materials, reflecting strong demand across all material categories and additional contributions from project business in DS&S. Display Solutions sales declined -12% organically, chiefly because of a continued drop in liquid crystals, which was accelerated by lower utilization at some of our Chinese customers.
Marcus Kuhnert
executiveSurface Solutions came in roughly flat, with organic sales rising 1% as cosmetics growth more than made up for the coatings decline, given tough comparables and automotive-industry challenges. EBITDA pre reached EUR 289 million, higher in reported terms but 6% lower organically. Versus a year earlier, the margin fell 160 basis points to 30.2%, largely because inflationary developments pressured gross margin. Before I hand things back to Belén, a brief word as well on the balance sheet and cash flow statement. On slide 14 you'll see the balance sheet grew a little relative to the end of December. Strong business growth and FX were the main forces behind that. Beyond that, the Exelead acquisition — financed entirely out of existing cash resources — brought some asset-side shifts, particularly a decrease in cash and cash equivalents. Right now the gap between purchase price and equity sits wholly within intangible assets as goodwill. On the liabilities side, pension provisions came down thanks to actuarial gains, and that, along with retained earnings and a positive at exit tax, pushed net equity up. Consequently, the equity ratio climbed further, from 47% to nearly 50%.
Marcus Kuhnert
executiveNow let's look at cash flows, which are on slide 15. We saw a solid operating cash flow of EUR 840 million, though that figure was notably lower than in Q1 of last year, largely because of phasing as well as tax positions and payables. The cash we spent on investing activities rose considerably, mostly as a result of buying Exelead, together with increased CapEx aimed at supporting our growth ambitions. Finally, the change in financing cash flow reflects a larger repayment of financial debt. With that, I'll turn things back to Belén for the ESG update and the outlook.
Belén Garijo
executiveThanks, Markus. I'm on slide 17 now, where I'll give you a quick update on ESG and flag a significant milestone we've reached on our roadmap. Over the last couple of months, we've been thoroughly assessing how we get to climate neutrality by 2040. As you may recall, under that ambition we established targets for cutting our Scope 1 to 3 greenhouse gas emissions by 2030. The Science Based Targets initiative has now confirmed the following emission targets as science-based. Our absolute production target of -50% for both Scope 1 and 2 emissions actually goes beyond what the SBTi requires to limit global warming to 1.5 degrees. For Scope 3 emissions, SBTi confirmed an intensity reduction target of -52% in relation to gross profit. To reach our goals, we've kicked off a range of initiatives and invested in technologies for reducing process-related greenhouse gas emissions, buying renewable electricity and improving energy efficiency. Beyond our climate targets, we've rolled out several programs to further boost our waste score. For instance, our SMASH Packaging initiative in Life Science will now be expanded with additional projects such as smarter in-film packaging in electronics and the so-called Slim Pack in our fertility franchise.
Belén Garijo
executiveYou can find more details in our 2021 sustainability report, which came out a month ago. So with that, I'll jump right into the outlook. But before I share the numbers, let me point back to what I said earlier regarding the operating environment becoming increasingly challenging. I'm now on slide 19. As you may recall, we already covered the subject of rising inflationary and supply chain pressures on our Q3 earnings call in November 2021. Since that time, the situation has evolved further, to put it mildly. In particular, the war in Ukraine and the recent lockdowns in China have introduced new challenges and compounded the ones already there. While we are clearly preparing for various scenarios, this chart sums up some of the key assumptions and mitigating actions that underpin our guidance. For instance, we assume energy supply shortages will persist through the rest of the year, yet will be confined to EMEA, with no outages anticipated. We expect continued volatility and upward pressure on input costs, but we assume only very minor shortages of raw materials. As for the lockdowns in China, we assume the situation will normalize around the end of Q2, and that we can make up for the lost business afterward in H2 this year, especially in Life Science and Electronics.
Belén Garijo
executiveJust so we’re clear, if China’s lockdowns run well past June, we still believe our guidance range accounts for that. To address these difficulties, we’re looking at other ways to sell and produce. Wherever and whenever feasible, we’re offsetting increased input costs through higher prices. We’ve also built up additional safety inventories of key raw materials and, naturally, we’re keeping a close watch on our suppliers. You can be sure that, as a science and technology company, we keep operating from a position of strength in handling these tough circumstances. Our margins remain appealing, our end markets are robust, and our systems and processes are built to adapt flexibly to a fast-changing environment and to safeguard our business effectively. That said, moving to slide 20, let me walk through the figures in more detail. For 2022, we now anticipate group net sales between EUR 21.6 billion and EUR 22.8 billion, EBITDA pre between EUR 6.6 billion and EUR 7.1 billion, and EPS pre between 9.6 and 10.5. This assumes organic sales growth of 6%-9% and organic EBITDA pre-growth of 5%-9%, consistent with the qualitative guidance we gave you in March.
Belén Garijo
executiveOn the currency side, we anticipate continued tailwinds, in the 3%-6% range for sales and 4%-8% for EBITDA pre, which is ahead of the 1%-4% and 2%-5% we guided before. The main driver here is the US dollar strengthening further. For a bit more color by business sector, please join me on slide number 21. As you can see, we still expect organic sales and earnings growth in 2022 to be supported by all three business sectors. We also continue to expect Life Science to be the fastest growing sector in terms of sales, followed by Self-Care and Electronics. Within Life Science, the outlook for the core business has improved, which offsets our reduced COVID expectations. That is simply strong testament to the quality and sustainability of growth in our Life Science sector, our largest business sector. On COVID, we now expect COVID sales in Process Solutions of up to EUR 700 million versus the up to EUR 900 million that we previously announced. At the same time, we confirm our guidance for below EUR 100 million in Research Solutions. We also still expect the margin in Life Science to be slightly down year-over-year. For Healthcare, our quantitative guidance is in line with our qualitative statements from March.
Belén Garijo
executiveOn the electronics side, we've gotten a bit more careful about margins, given the inflation we anticipate. That said, many thanks for listening, and we're ready now to take any questions you have. Thanks.
Kai Beckmann
executiveJust one comment from me before we begin. I'd ask each of you, please, to keep it to no more than two questions per person. That way, every question you have will actually get heard first. Thanks so much. Let's open the Q&A now, please.
Operator
operatorThanks. We're moving into the question-and-answer portion now. If you'd like to put a question to our speakers, press star one on your phone keypad at this point to join the queue. After we announce your name, you'll be able to ask. Should your question get answered before your turn arrives, press star two and it will be withdrawn. Those of you on speaker equipment should pick up the handset first, then make your selection. Please hold for a moment while we take the first question. Matthew Weston with Credit Suisse is first today.
Matthew Weston
analystThank you so much. I have two questions, if I may. The first concerns growth in life science. Belén, I completely understand your confidence regarding how this business will grow, yet I'm somewhat puzzled when I try to reconcile the figures. You delivered 10% organic growth in Q1, and the COVID comparison was an easy one. Marcus has already noted that China is going to be a meaningful drag in 2Q, but according to your guidance, underlying growth in life science really needs to speed up during the second half of the year. I would very much like to grasp what is behind that pickup. Does it come from new capacity you have brought on? Do you have solid visibility into the order book? Any color at all would set my mind at ease. My second question: you said the prolonged Chinese lockdowns sit inside your guidance range, or are captured by that range. I am quite focused on German energy rationing, and I recognize it might not occur, but I would like to grasp what share of your business depends on manufacturing based in Germany, and what steps you can take to try to safeguard it amid the uncertainty as we head toward year-end.
Belén Garijo
executiveHi, Matthew. I’ll take the second question first, and after that I’ll have Matthias comment on growth in life science. I believe you mean gas — specifically the possibility of a gas embargo in Germany. Were such an embargo to happen, our biggest exposure would of course be in Europe, and Darmstadt accounts for 50% of the gas we consume in Europe. Naturally, from the very start of the conflict, the war, we have been laying out our mitigation plan, and at this point we are highly confident that we are very well prepared to prevent any disruption at our production sites in Darmstadt. Maybe Kai can give a few more specifics about what that plan includes.
Kai Beckmann
executiveHey Matt, it's Kai here. Our plans call for swapping out the gas we use with alternative energy sources — oil and grid electricity among them. Given that, I'd say we're confident about addressing the whole scope so that production at Darmstadt keeps running.
Belén Garijo
executiveMatthias?
Matthias Heinzel
executiveHi, Matthew. This is Matthias, and I'll take your question. Yes, we are absolutely reaffirming the guidance we've set for the year for Life Science at 7%-10%. It really matters that we separate the dynamics of COVID demand from those of the core business. As this quarter has shown, even with COVID declining, we've compensated through very strong growth in the core business. Basically, PS core runs two points above the total figure for Process Solutions, and the same holds for Research Solutions, where we report 2% for the overall business. Once I strip out the core business, we're up 5%. Another major reason for our confidence across the full year is, as you pointed out, the order intake and the order book. Looking at order intake — meaning all orders placed during the quarter and booked in that quarter — those are still rising. Order intake is up slightly versus last year. It's up slightly on a sequential basis. Although it's falling on the COVID side of the business, it's up substantially for the core business. Taking all of that together, as Belén said, we're dealing with plenty of macro challenges, but our confidence in the core business is very strong.
Matthias Heinzel
executiveWe also have, as we said earlier, a capacity base that keeps expanding and is now coming online. This rising core demand is now meeting the capacity growth we have.
Richard Vosser
analystMuch appreciated.
Peter Guenter
executiveThanks, Ram.
Operator
operatorThe next question we have is from Richard Vosser at JPMorgan.
Richard Vosser
analystHi there, and thanks for the question. I wanted to ask about how the situation in Ukraine is affecting clinical trials. Marcus, you mentioned that seeking additional patients is one of the steps you're taking across your clinical trial program, and that makes sense. How should we think about the effect on timelines, especially for ibrutinib, if you're able to comment on that? A bit more detail there would be very helpful. Maybe also a pharma-related question on Mavyret. You noted a 15% rise in demand from new patients in the U.S., which looks good. How are the dynamics outside the U.S. for Mavyret when it comes to new patients and returning patients? That would be helpful as well. Thanks very much.
Peter Guenter
executiveYes, Richard, thank you for that question. I'll address both parts. First, on ibrutinib, as Marcus said at the start, this clearly isn't a surprise to you. It's a difficult situation from a clinical trial standpoint, and that's something common across the industry and certainly not specific to Merck. A few points regarding mitigation. To begin with, we noted earlier that we've implemented several proactive steps, such as raising study medication stock levels in the regions affected. We also worked hard to make sure we keep patients on study in the affected territories—for instance, by relocating them to places where they can keep taking part in our trial, whether that's within Ukraine or, incidentally, beyond Ukraine. Now, to directly address your question, and to Marcus' point, we have in fact decided to add more patients outside those countries. We also took the chance—and this matters—to amend our protocol so that it is event-driven, which we think is the best approach given these circumstances. This design, which incidentally is commonly used in MS trials, as you know, was submitted to major health authorities, and it will let us draw on more data from the patients remaining in the trial and help reduce the impact caused by those circumstances.
Peter Guenter
executiveOn timelines — you heard us say before the war that we'd have the clinical trial data in-house during Q4 2023, and that's still our goal, taking into account all the mitigating measures and the protocol change I just walked you through. Naturally, since the protocol is event-driven now, the precise date would hinge on accruing the required events, just as it does for the other major competitors in the BTKi space. As for your Mavyret question, you said new patients were up 15% in the U.S. — allow me to correct that slightly. That figure is for new patients globally, not necessarily the U.S. To add a bit more color: in the U.S., the high efficacy market remains depressed, as you've likewise heard from some of our peers in that market. The good news is that we're holding our market share, unlike, for instance, the S1Ps, which are losing share to the anti-CD20s. Across the Atlantic, in key European countries, we hold strong positions, and we keep strengthening them, since we're still gaining share within the dynamic segment of the high efficacy market.
Peter Guenter
executiveAll told, with that EUR 189 million, we landed exactly where consensus had us. And as this year plays out, I feel good about seeing the payoff from the fairly solid momentum we're seeing in new patient starts.
Richard Vosser
analystMuch appreciated.
Operator
operatorGary Steventon from BNP Paribas Exane has the next question.
Gary Steventon
analystOh, great. Thank you for taking the questions. Just to follow up on Mavyret and perhaps the healthcare guidance, please. It looks like the healthcare top line guidance might be slightly widened, just translating the previous solid into the new 4%-7% range. So it'd be helpful if you could share your thoughts here and what kind of recovery for Mavyret might be assumed in a 4% growth scenario versus 7% or really what the key swing factors are for that perhaps slightly widened healthcare guidance. Then, a question on Life Science and China as well, please. I think it'd be helpful if you could just remind us of the sales exposure for each of the three divisions to the Chinese market. Specifically on Life Science, you recently announced the investment in single-use capacity for bioprocessing. So I'm just wondering how this sits within the network. Is it mainly to service the domestic Chinese market? And if so, kind of how a significant driver of future growth do you think China should be? Or is it more to shift production out to kind of European and U.S. markets on a relative basis which might support margins longer term? Thank you.
Peter Guenter
executiveThanks. I'll take that first question. When you look at the 4 to 7, it isn't really any one product or any one cause. There are many areas where we sit inside a range, right? Particularly when it comes to recent launches. So Mavyret, obviously, contributes to that variability within the range. BAVENCIO as well — we still have many launches ahead of us, so we don't know precisely when pricing and reimbursement will happen. As you know, that is always somewhat variable. For instance, I can share that with BAVENCIO we just secured reimbursement in Spain in May, and we obtained reimbursement in Italy in April. We're continuing to roll the product out right now. Naturally, that brings a certain amount of variability with it. Then maybe the final item I'd mention is fertility in China. Even though fertility in China accounts for under 20% of fertility sales worldwide, we may of course see, in certain areas of China, Shanghai for example, a temporary impact from the lockdowns on the fertility business.
Matthias Heinzel
executiveOkay. Thank you, Peter Guenter. This is Matthias Heinzel speaking. I'll now address both of your Life Science questions. Let's start with China. In terms of our regional breakdown, Asia as a whole represents roughly 25% of total Life Science, while China accounts for about 10%. That spans our whole business — Process Solutions, Research Solutions, and Applied Solutions. First, our plants in China and in Tonglu, Wuxi are fully operational, correct? We're running at full capacity. But like most other companies, the lockdown is affecting us, particularly around Shanghai. That will definitely have a near-term effect on us, especially when we look at Q2. Q1 saw no impact. Getting goods out of the warehouses is currently somewhat difficult. Depending on how long this lasts, we anticipate recovery over the full year. All of that is essentially reflected in our guidance. Now the second part of your question, on single use. As of today, we have a strong footprint for single use in the U.S. at our Danvers facility. We've announced a global expansion into Europe, and went live with our multi-site facility in kind of two steps.
Matthias Heinzel
executiveSo we've now announced the single-use capabilities that we've built up in Wuxi, China. Really, when it comes down to it, our goal is a very strong footprint globally. Basically, that China facility ought to serve the fast-growing market coming out of China.
Peter Guenter
executiveAlright, thanks.
Operator
operatorJames Quigley from Morgan Stanley has the next question.
James Quigley
analystHi, thank you for taking my questions. I have a couple regarding margin development. On the electronics side, could you provide a bit more detail on how EBITDA is developing? You said that perhaps the lower end of the guidance has been nudged down slightly. But could you give us a sense, with some additional specifics, of your pricing initiatives in semis and any other levers you have, or perhaps don't have, in Display Solutions and Surface Solutions? On pharma, you noted in the release that R&D declined in absolute terms, so how should we expect that to trend over the remainder of 2022? Could you speak to your flexibility for investment in pharma, which comes with the termination of the Ventrafast program in lung cancer. Do you have any plans to speed up investment in certain areas, or to preserve flexibility for in-licensing or the R&D tied to in-licensing? Or should we expect that R&D savings will keep being an EBITDA driver? Any thoughts on this would be great. Thank you.
Peter Guenter
executiveJames, I'll take the electronics question first. You asked about how margins are developing. In semi, we do have pricing levers, and margin development in semi is stable while we've already begun, of course, investing in future growth through additional R&D investments as well as our capacity investments, which definitely weigh on margins too. Currently there is no margin progression. However, we enjoy stable margin. Display margin development continues to be impacted. This is not a situation based on inflation. It's the market development that we've reported for a couple of quarters — meanwhile a couple of years. At present this is no longer fully compensated by the semi development. In Surface, we do have a positive pricing environment too. In Surface, we even expanded our margin slightly, which is in part based on our transformation activities and on cost initiatives in Surface too. There's a combination of different factors that, in a mix, has led to the margin assumptions that we've put forward in our guidance.
Matthias Heinzel
executiveSure, James. On the R&D spending question, going forward you should figure that the proportion we're at right now will stay roughly flat relative to sales. There are a lot of moving pieces in that R&D number, as you're aware. And yes, to your point, Ventrafast is indeed out. You've seen in the catalyst that we have both entanerone in 2 phase II studies, and we'll kick off the exepenafamcib initiation trial over the summer. I think when we look across the R&D portfolio, we've got sufficient flexibility to keep doing what needs to be done and to get the most out of the assets we hold. At the same time, we want to make sure our ratio to sales stays more or less in the range you're seeing now.
James Quigley
analystThanks a lot. Appreciate it.
Operator
operatorSachin Jain from Bank of America has our next question.
Sachin Jain
analystJust two quick questions, if I may. First, on COVID sales in Process Solutions, could you comment on how you expect those to be phased through the year? I believe the first quarter came in at roughly EUR 150 million. Should we anticipate that level as the full run rate for the rest of the quarters? I just want some sense of the drag to expect from COVID going forward, given the different phasing in 2021. The second is simply an update on the MAVENCLAD patent term extension. I think it was turned down in the U.S. when you appealed, and you're still waiting to hear from a couple of European countries, Germany and the U.K. Any news on that would be very helpful. Thank you.
Marcus Kuhnert
executiveYeah. Hey, Sachin, this is Matthias. I'll take your first question. For sure, I mean, what we're looking at is more of a flat trend with COVID — perhaps even a modest decrease as the quarters go by, and that's roughly what we've factored into our adjusted top-line guidance. Right now, obviously, everything hinges on how the virus and its rollout unfold. Still, with Omicron widespread and symptoms milder, our expectation is that this stays fairly flat rather than expanding across the year.
Peter Guenter
executiveYeah, Sachin, regarding your question about MAVENCLAD and where things stand on the patent side — the short answer is nothing new to report. The appeal concerning the patent term extension is still awaiting a decision in the U.S. As you're aware, over in Europe we've secured a certain number of SPCs in several key countries, including Spain, France, and Italy. The remaining SPC applications haven't been decided yet. These things move forward on a country-by-country basis, so we'll have to wait and see what happens down the road.
Sachin Jain
analystThanks.
Operator
operatorNext up is Keyur Parekh from Goldman Sachs.
Keyur Parekh
analystHello, two questions if I may. On the first, I'm hoping you could provide somewhat more granular direction regarding the overall picture on a quarterly basis. You're plainly calling out certain headwinds heading into the second quarter and something of a rebound as we move toward the latter half of the year. I'd just like to know, when we consider roughly the year-over-year comparison for the second quarter, how would you describe it? Second, on the cost inflation side, I believe slide 19 addresses this somewhat. I'm curious whether you could offer a little more quantitative detail on what has been factored in, or what is assumed within your guidance, particularly with respect to input cost. Thank you.
Belén Garijo
executiveHi. Look, we typically don’t provide precise quarterly guidance, right? The challenges we discussed on Q2 relate solely to the China lockdowns, which, you know, had no impact on our business, or very little impact on our business in Q1. Obviously, we’ve made assumptions regarding life science and electronics and healthcare. As Matthias mentioned earlier, we expect Q2 to depend heavily on how the lockdowns evolve. We have distribution challenges, basically, so we expect to catch up on those sales in future quarters. That is the only specific challenge I’m mentioning for Q2. Marcus, would you like to talk about inflation?
Marcus Kuhnert
executiveFrom where I sit, there isn't much more to say. In the guidance we laid out, our view is that fairly elevated inflation will be with us across all of 2022, and on one side that comes from certain raw material cost pressures. On the other side, it comes from higher freight and logistics expenses as well as energy prices, which incidentally also affected us during the first quarter. So on the inflation front, there probably won't be a great deal of new information as we progress further through the year. The main item that could weigh somewhat on the second quarter is, as Belén just said, a clearer effect from the China lockdowns, which we anticipate will ease gradually once we get into the back half of the year.
Keyur Parekh
analystThanks.
Operator
operatorNext up is Falko Friedrichs from Deutsche Bank.
Falko Friedrichs
analystThanks. Good afternoon. First, can you give an exact figure for the COVID-related sales in Q1? Apologies if I missed it. Second, regarding the semiconductor materials business, is there any risk the demand side might be hurt by all the macro stuff happening around us, inflation and everything, or is that not much of a risk going forward? Thank you.
Matthias Heinzel
executiveYeah. Hey, Falko. Matthias here. Like I said earlier, we provided an upper bound for our COVID figure of roughly EUR 700 million. Your colleague, I think, asked before and worked out how Q1 sort of spreads across the year. That should give you a sense of what Q1 looked like. If you annualize that, I think you come quite close to it.
Peter Guenter
executiveFalko, I might handle the semi question. On the demand side, we aren't hearing anything negative from our customers. It's quite the reverse. That's true. Their factories are operating at full utilization. They're still working to recover from what people call the chip crisis, and that backlog is still there.
Kai Beckmann
executiveThe market forecast calls for 8% growth in MSI, or wafer starts, and that's holding up pretty well. We're ready for sustained strong demand on the end-use side across all the various semiconductor areas.
Falko Friedrichs
analystAll right, thanks.
Operator
operatorDaniel Wendorff from Oddo BHF has our next question.
Daniel Wendorff
analystYes, and thank you for taking my questions as well, likewise on my end. So I have one question about Life Science. Regarding the strong underlying demand development for your core business, particularly in Process Solutions, could you perhaps discuss a little where that is coming from? You also mentioned the strong order development in Process Solutions. I would be interested in a figure such as order intake growth excluding the COVID part. So if you could help me there, that would be nice. Then a follow-up question, really on Falko's question, for electronics or Semiconductor Solutions. Is there any risk that supply chain topics might arise for you as a supplier, and also depending on certain products? From my understanding, that was also part of the business in Display Solutions, but maybe you can provide more color here. Thank you.
Matthias Heinzel
executiveHey Daniel, Matthias here. Let me take the first question. To start with, when we discuss our strong core business, it genuinely spans all 3 businesses. Research, applied, and process solutions all delivered quite strong core business growth, if you will, right? We typically focus on process solutions, but looking at applied too, that was very strong. Research as well, if I exclude COVID with 5%, really also in line with our mid-term guidance. It cuts across sectors. Clearly, we're strong in pharma biotech, but in applied too, for instance, we have industrial testing, which serves the food and beverage industry. There as well we saw a very nice uptake. The key point here is that it truly spans every business segment and every region. Second, your question about Process Solutions. Actually, we don't break out our order intake into further detail. As I said earlier, we still see a slight year-over-year order intake increase, and also sequentially from Q4 to Q1, a sequential order intake increase with a still very healthy book-to-bill ratio. Then very importantly, the dynamics within that order intake and leading to a strong order book — the quality, if you will, and the speed of the business now sits much more toward the core of the business versus COVID.
Matthias Heinzel
executiveIf you look at it in sequence, core business order intake rose significantly from Q4 to Q1.
Kai Beckmann
executiveDaniel, I’ll address the question about the semiconductor supply chain. We are handling our supply chains extremely tightly over, you know, a few quarters, and credit goes to the supply chain team. Each raw material gets tracked individually, wherever feasible we use dual sourcing, we check dependencies both direct and indirect, and we examine port congestion—last year in the U.S., this year in China. None of our customers has been let down by a missed delivery, so this is monitored very, very closely. We lack a crystal ball, yet on our side we do not anticipate any constraints. Naturally, we remain in touch with customers in case they rely on other materials and might encounter shortages. So far nothing like that has come up, and that is how we monitor the supply situation. Based on what we know today, we do not expect any shortages.
Daniel Wendorff
analystI appreciate that.
Operator
operatorSimon Baker from Redburn has our next question today.
Simon Baker
analystThanks for taking my two questions. To follow up on the semi cycle question: one of my colleagues attended the SPIE Lithography conference a couple of weeks ago, and he came away with the impression that EUV adoption is likely a bit slower than some had anticipated. I'd like to hear your views on that, and honestly, how much it matters for Merck. Does a faster EUV rollout help you or hurt you, or does it not really make much difference? Second, on healthcare: at the end of April, a paper in Nature suggested that someone has identified TLR7 gain-of-function genetic variants, which clearly bodes well for your work with enpatoran in lupus. I'd like your perspectives on that, and also whether you are doing or have done any sequencing in the planned phase II study that began in Q1. Thanks so much.
Kai Beckmann
executiveSimon, regarding the SPIE discussion on EUV: the delay still represents only a small piece of the materials business tied to EUV throughout the industry, not solely for us. That postponement in EUV adoption isn't material. Conversely, we're seeing faster node transitions among all our leading-edge customers. Looking industry-wide, we actually observe more of the opposite right now than what's been indicated, something easily tracked through our R&D projects, which even show some acceleration in areas like progressing through 3D NAND layers, NAND, and smaller node sizes in advanced logic. I'm not pessimistic about how quickly our leading-edge customers are innovating. Yes, Simon, to your question, the answer is yes. I think the Nature publication actually strengthens our hypothesis concerning TLR7/8 and the part it plays in lupus pathogenesis.
Peter Guenter
executiveOur view is that this really does matter for both innate immunity and the adaptive immune response. In fact, that Nature paper simply strengthened our hypothesis that TLR7/8 plays a part in SLE pathogenesis. WILLOW is a proof-of-concept, dose-finding basket trial looking at how effective and safe napataran is in systemic lupus as well as cutaneous lupus. We dosed our first patients not long ago. That makes us quite pleased, and we anticipate enrolling approximately 440 patients.
Belén Garijo
executiveAll right, thank you very much.
Operator
operatorAnd now for our last question of the session, we have Florent Cespedes from Société Générale on the line. Florent, good to have you — please go ahead, your line is open.
Florent Cespedes
analystHello, Yuri. Sorry about that. Thanks so much for taking my question. This is Florent Cespedes from Société Générale. I have two quick questions. First, a follow-up regarding the guidance. Would you mind giving us some detail on the assumptions that might lead you to the low end of the guidance range? We understand that on the inflation side, there shouldn't be much over the remainder of the year, so it appears most of the uncertainty stems from China and the lockdown currently in place. That's my first question. My second concerns fertility. You mentioned something of a return to normal, with +4% top line growth in the first quarter. It seems you're encountering some challenges in China. If you could just provide a bit more detail on how this business is performing?
Belén Garijo
executiveThanks a lot. Florent, I’ll take your first question. As you’re aware, we’re operating in a highly complicated environment, and we’ve put several mitigation plans into action: using alternative channels for sales and production, passing along higher input costs through pricing fixes whenever and wherever that’s feasible, and building up safety stocks. In the end, uncertainty exists on several fronts, correct? I brought up the China lockdowns. I noted that even if those lockdowns run well past June, we think our guidance still covers it. Given how uncertain and volatile things are, we need to give you a sensible picture. What I think is a very transparent picture of the assumptions behind our guidance. That’s what I can offer on your first question. As for your second question, Peter will cover fertility.
Peter Guenter
executiveYes. Thank you, Belén, and hello, Florent. On fertility, to start with, we enjoyed a solid first quarter. Growth is carrying on in what we refer to as the post-pandemic phase, at 4.3%, which aligns with the guidance we gave for the midterm. That first quarter leaves us quite pleased. Then, regarding your question about China — as I noted earlier on this call, the fertility business in China, the whole of it, accounts for under 20% of the worldwide business. And naturally, inside that, if a temporary lockdown happens in Shanghai, that represents just a small portion of it — a comparatively small portion, correct? Finally, we have also observed previously that once lockdowns loosen, a catch-up effect on fertility tends to follow. We witnessed exactly that last year in Europe and the U.S., for instance. We would expect the same here too. We aren't especially concerned, though I would call it a point to watch.
Florent Cespedes
analystAlright, thanks a lot.
Belén Garijo
executiveOkay, Terry here.
Operator
operatorYes. I believe that covers every question. So with that, I'm glad to pass things over to Belén for any closing words. Belén, closing remarks.
Belén Garijo
executiveRight, and I'll keep this brief. Thanks to all of you for the ongoing interest you've shown in Merck. To sum up, the year got off to a really robust start, with sales and earnings both growing by double digits. Even though conditions for doing business are getting tougher by the day, we're reaffirming the organic growth targets we set for this year. Naturally, our strategic priorities will keep getting our full, undivided attention when it comes to execution. Do bear in mind the point I made earlier: as a science and technology company, we keep operating from a position of strength when we have to steer through uncertain environments. Our margins are highly attractive, our end markets remain robust, and our systems and processes are built to adapt nimbly to this fast-moving environment and to shield our business effectively. On that note, I simply wanted to share that our Capital Markets Day is set for October sixth, to be held at our headquarters in Darmstadt. Details will be sent along by our IR team in due course. It would be a pleasure to welcome as many of you as possible. Thanks once more, and goodbye.
Operator
operatorThanks, everyone, for joining us. That wraps up today's call. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.